Impedimed Limited · ASX:IPD
Impedimed — Bell Potter Conference 2024
15 slides from Impedimed's conference presentation, Nov 18, 2024
Slide 1: Presentation – Bell Potter Conference
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 18 November 2024 Companies Announcements Office Australian Securities Exchange Presentation – Bell Potter Conference ImpediMed Limited (ASX:IPD) releases the attached presentation t
Slide 2: Forging a new Standard of Care
ImpediMed Limited Forging a new Standard of Care Bell Potter Conference, 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance,
Slide 4: Agenda
Agenda ImpediMed – Forging a new standard of care Platform Technology with multiple applications Strategy - Focus on accelerating sales and controlling costs First Application - Breast Cancer Related Lymphoedema New Team to execute - New Board & New Executive Team Financials - Key Metrics & Q1 FY25
Slide 5: Platform Technology
Platform Technology SOZO® Digital HealthPlatform One device - Multiple FDA cleared applications • Lymphoedema – FDA clearance, CE Mark • Body composition – FDA clearance, CE Mark • Heart failure – FDA clearance, CE Mark • Protein calorie malnutrition – FDA clearance, CE Mark • Renal Failure – CE Mar
Slide 6: Immediate strategy
Immediate strategy Execute to breakeven with a focus of sales, marketing and clinical execution in BCRL 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Progress to break ev
Slide 7: SOZO BIS: All elements in place to forge the new Standard of Care
SOZO BIS: All elements in place to forge the new Standard of Care $600m Positive Global Clinical Trial BCRL TAM 1200 patient trial: Statistically Significant Widespread & Increasing US Payor Coverage Lower Progression to Chronic Lymphoedema1 FDA cleared • 23 US States now at Critical Mass (>80% cove
Slide 8: Forging a new standard of care for Breast Cancer Survivorship
Forging a new 4M+ 82% standard of care for • US breast cancer Breast cancer patients are at risk of survivors1 arm lymphedema due to their Breast Cancer treatment over their 5-year survivorship journey5 Survivorship 310k Newly diagnosed US breast cancer patients every year1 • Lymph node surgery • R
Slide 9: SOZO BCRL: Replaces time consuming SOC with early, objective & fast detection
SOZO BCRL: Replaces time consuming SOC with early, objective & fast detection for Breast Cancer Related Lymphoedema Current Standard of Care (SOC) Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, Subjective or Time-Consuming Guideline Supported, Reimbursed, Early, Objective & Fas
Slide 10: ImpediMed Board – New Team with Global Experience
ImpediMed Board – New Team with Global Experience Governance Project delivery Culture Performance Non-Executive Directors Executive Directors Global Company Experience • Pfizer Christine Janelle Delaney Fiona Bones Andrew Grant Dr Parmjot Bains McGregor Grant • Google Emmanuel- Non-Executive
Slide 11: New World Class Executive team
New World Class Executive team US healthcare market Medtech commercialisation Sales execution Creating long-term value Executive Directors Executives Dr Parmjot Bains McGregor Grant Dr Steven Chen Tim Benkovic Julie Kuhlken Aaron Ogilvie Ashley Munoz Dennis Schlaht CEO / Managing CF&OO / Chi
Slide 12: Key forward looking metrics improving
Key forward looking metrics improving Q1 FY25 Pipeline Metrics and New Payor Coverage Metrics FY25 Q1 Sales Pipeline Updated Mid Q2 FY 25 585 devices Critical Mass States1 34% increase vs Q4 FY24 23 States +7 vs Q1 FY25 Q1 FY 25 NAPBC Standard Inclusion Updated Mid Q2 FY 25 SOZO at 143/570 254.7m Ac
Slide 13: Financial momentum continues with record quarterly increase in TCV
Financial momentum continues with record quarterly increase in TCV1 Q1 FY25 Financial Highlights SOZO Core Business Quarterly TCV # SOZO units SOZO Core sold U.S. Business TCV 28 $4.8 million1 22% vs Q4 FY24 40% vs Q4 FY24 Total SOZO Core revenue Business ARR • 6 networks contracted with 2-3 devices
Slide 14: SAAS Business with a Global Installed Base and ARR growth
SAAS Business with a Global Installed Base and ARR growth Global Installed Base SOZO Annual Recurring Revenue1 Units ROW Installed Base US Installed base Low churn 3% annualized ARR up 21% vs Q1 FY24 1.Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognis
Slide 15: The Value Proposition
The Value Proposition Multiple Regulatory Clearances Lymphoedema Heart Failure Reimbursement Renal Failure 73% of US Body Comp Successful Insured Lives covered Global RCT Lymphoedema Critical mass prevention coverage in 23 US States Guideline and Initial TAM Standard $600M Inclusion Multi-Applicatio